MORRISTOWN, N.J.--(BUSINESS WIRE)--Intendis, Inc., part of the Bayer Group, which makes Finacea® (azelaic acid) Gel, 15%, has developed the first Smartphone application (app) designed specifically for those with mild to moderate rosacea. The Rosacea App provides information, support and helpful tools that can be used to learn more about rosacea and to help manage its signs and symptoms. The Rosacea App is available free of charge to anyone who has an iPhone, Blackberry or Android Smartphone.
The Rosacea App provides instant access to an abundance of helpful information about the many issues faced by people with rosacea. Not only does it serve as a source of information, it also acts as a personal daily journal. A rosacea flare up can be caused by any number of triggers – from the weather, to different foods, to alcohol, to skin care products. It is important to keep track of potential triggers so that steps can be taken to help avoid them. The Rosacea App features a Trigger Tracker tool that can be used to track and manage these triggers. It also delivers daily Weather Alerts to inform users of a possible weather trigger. The Rosacea App is also equipped with a Substitution Finder that provides alternative suggestions for foods and drinks that can be used in place of those that may be triggering a rosacea flare up. The Rosacea App offers an Assessment Tool that helps one identify whether they may suffer from rosacea. It also provides answers to many of the Frequently Asked Questions about rosacea and provides an overview of the treatment options available – including a discussion about Finacea® (azelaic acid) Gel, 15% and its effectiveness in treating the bumps, pimples and associated redness of mild to moderate rosacea.
The Rosacea App provides a coupon for Finacea® that can be used at the pharmacy, directly from the Smartphone. It also gives the user the opportunity to register for special offers or to sign up for a monthly newsletter. By completing the built in questionnaire in The Rosacea App, the user will gather important information about their condition that they can take and discuss with their healthcare provider. The Rosacea App has been created with the special informational and educational needs of the sufferer of mild to moderate rosacea in mind.
INDICATION & USAGE
FINACEA is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.
IMPORTANT SAFETY INFORMATION
FINACEA is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. FINACEA is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety - Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with a dark complexion, these patients should be monitored for early signs of hypopigmentation.
Other than FINACEA, Intendis, Inc. (part of the Bayer group) does not promote or endorse any products or recommendations made by third parties. All products and brand names listed are the property and responsibility of their respective trademark and copyright holders.
Please see full Prescribing Information for FINACEA at www.finacea-us.com.
FINACEA is a registered trademark of Intendis, Inc.
Intendis is part of the Bayer Group.
About Intendis
Intendis Inc. is an U.S. based affiliate of Intendis GmbH, a fully integrated pharmaceutical company based in Berlin, Germany. As part of the Bayer Group, Intendis is dedicated to Dermatology and focuses on the development and marketing of high quality, innovative topical therapies, targeted to treat skin disorders. Intendis’ objective is to become a leading partner in the field of dermatology.
Find out more at www.intendis-us.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.